10-Q: Viskase Holdings Reports Q1 2026 Results Amid Merger Integration

Sentiment:

Quarterly Report


Viskase Holdings, Inc. reported a net loss of $6.7 million for the first quarter ended March 31, 2026, with net sales decreasing 8.1% year-over-year, impacted by volume declines and restructuring efforts.

Capital raiseIn January 2026, Viskase issued and sold 25,862,070 shares of its common stock at $0.58 per share, resulting in aggregate cash proceeds of approximately $15.0 million through a private placement with an affiliate of Icahn Enterprises L.P.The company had $15,000 in proceeds from a private placement of common stock contributing to the net cash provided by financing activities in Q1 2026.
Worse than expectedNet sales decreased by 8.1% to $86.5 million, primarily driven by a volume-related decrease of $13.0 million.Gross margin decreased by 37.5% to $9.0 million, primarily driven by lower volumes of product sold due to temporary capacity constraints.Net loss increased to $6.7 million from $13.6 million in the prior year, although the loss per share improved due to a higher share count.Net cash used in operating activities was $16.3 million, a significant deterioration from $0.1 million provided in the prior year.

Summary

  • Viskase Holdings, Inc. reported a net loss of $6.7 million for the first quarter ended March 31, 2026, compared to a net loss of $13.6 million in the prior year period.
  • Net sales for the quarter decreased by 8.1% to $86.5 million, primarily due to a volume-related decrease of $13.0 million, partially offset by price/product mix increases and favorable foreign currency impacts.
  • Gross margin declined significantly by 37.5% to $9.0 million, largely attributed to lower product volumes from temporary capacity constraints.
  • Operating expenses decreased by 53.7% to $13.3 million, mainly due to the absence of a $12.1 million asset impairment charge recorded in the prior year's quarter.
  • The company's Senior Credit Facility maturity date was extended to August 13, 2027, through a Seventh Amendment.
  • Substantial doubt exists about the company's ability to continue as a going concern, dependent on refinancing its Senior Credit Facility before its August 2027 maturity.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the reported net loss, declining sales, reduced gross margin, and the explicit statement of substantial doubt regarding the company's ability to continue as a going concern, despite the extension of debt maturity.

Positives

  • Favorable foreign currency impact of $4.3 million on net sales.
  • Increase in selling price and product mix contributed $1.0 million to net sales.
  • Operating expenses decreased by 53.7% due to the absence of a significant asset impairment charge from the prior year.
  • The maturity date of the Senior Credit Facility was extended to August 13, 2027, providing additional time for refinancing.
  • The company's disclosure controls and procedures were deemed effective as of March 31, 2026.

Negatives

  • Net loss of $6.7 million for the quarter.
  • Net sales decreased by 8.1% to $86.5 million, driven by a $13.0 million volume decrease.
  • Gross margin decreased by 37.5% to $9.0 million due to lower volumes and temporary capacity constraints.
  • Significant decrease in North America net sales ($16.8 million) due to reduced sales volume from restructuring-related capacity issues.
  • Substantial doubt exists about the company's ability to continue as a going concern, contingent on refinancing its Senior Credit Facility.
  • Net cash used in operating activities was $16.3 million, a significant decrease from the prior year's $0.1 million provided.

Risks

  • The company's ability to continue as a going concern is dependent on obtaining adequate refinancing of its Senior Credit Facility before its maturity in August 2027.
  • Geopolitical and economic uncertainty, including inflation, risk of economic slowdown, fluctuating interest rates, tariffs, supply chain disruptions, and war, could have material adverse effects on the business.
  • Increased input costs, disrupted supply chains, reduced consumer demand, tighter financial conditions, and impaired access to capital markets are potential consequences of macroeconomic and geopolitical conditions.
  • Competitor pricing may adversely affect net revenue if competitor casing prices fall relative to Viskase's products.
  • The company may not be able to realize the cost savings and benefits anticipated from the 2025 Restructuring Plan.
  • Pending or future legal proceedings and regulatory matters could have a material adverse effect.
  • Changes in the cost or availability of raw materials and changes in energy prices or other costs could impact results.
  • Pricing pressures for products could negatively affect revenue.
  • The cost of and compliance with environmental laws and other governmental regulations pose a risk.
  • The company may not be able to utilize its net operating losses and tax credit carryforwards.
  • The company may not be able to meet, or seek an exemption to, the 10% public float requirements for the OTCQB market.

Future Outlook

The company believes that net cash generated from operating activities, cash on hand, and available borrowings under its Amended Senior Credit Facility will be adequate to meet liquidity and capital requirements for the foreseeable future. However, substantial doubt exists about the company's ability to continue as a going concern, contingent on refinancing its Senior Credit Facility before its August 2027 maturity.

Management Comments

  • Viskase Holdings, Inc. (previously Enzon Pharmaceuticals, Inc.) is a worldwide leader in the production and sale of cellulosic, fibrous and plastic casings for the processed meat and poultry industry.
  • The company's business strategy is to continue to improve operational efficiencies, product quality and throughput by upgrading existing production facilities and adding resources in high growth markets through new capital investments.
  • Viskase is focused on reducing extrusion, shirring and printing waste through equipment upgrades and an ongoing effort to redefine product mix.
  • The company does not expect to incur any significant additional cash charges during the remainder of 2026 related to the 2025 Restructuring Plan and does not anticipate these cost-saving measures will impair its ability to conduct any of its key business functions.

Industry Context

StockSavvy.ai notes that Viskase operates in the non-edible casings market for processed meats and poultry, a sector characterized by capital-intensive extrusion operations and labor-intensive finishing. The industry's operating results are historically sensitive to the global balance of capacity and demand. Viskase is one of the largest global producers in this niche.

Comparison to Industry Standards

  • Viskase is one of the two largest worldwide producers of non-edible cellulosic casings for processed meats.
  • Viskase is one of the three largest manufacturers of non-edible fibrous casings.
  • The company's current and planned cellulosic production capacity is believed to be in balance with global demand, aligning with industry equilibrium.
  • The industry's extrusion facilities operate continuously due to a timed chemical process, a standard operational characteristic.

Legal Proceedings

  • The Company is subject to legal proceedings and claims that arise in the ordinary course of business. The ultimate outcome of these matters is inherently uncertain, and there can be no assurance that their resolution will not have a material adverse effect on the company's financial condition or results of operations.

Related Party Transactions

  • As of March 31, 2026, and December 31, 2025, IELP owned approximately 93.68% and 92.8% of Viskase's outstanding common stock, respectively.
  • In January 2026, Viskase entered into a securities purchase agreement with an affiliate of Icahn Enterprises L.P. (IELP) to issue and sell shares of its common stock, resulting in aggregate cash proceeds of approximately $15.0 million.
  • Viskase Companies became a member of the consolidated group of IEP Corporate Subsidiary for U.S. federal income tax purposes, entering into a tax allocation agreement.
  • IELP has agreed to indemnify Viskase and its subsidiaries from losses resulting from any imposition of certain pension funding or termination liabilities that may be imposed on them as a result of being a member of the Icahn controlled group.

Stakeholder Impact

  • Shareholders: The net loss and going concern doubt may negatively impact shareholder value. The private placement in January 2026 diluted existing shareholders.
  • Creditors: The company's ability to refinance its Senior Credit Facility is critical for its continued operation, impacting creditors.
  • Employees: Restructuring plans and potential future actions could impact employment. Severance costs were incurred in relation to the 2025 plant closure.
  • Suppliers: Continued operations and financial health are important for supplier relationships.

Next Steps

  • Refinance the Senior Credit Facility before its maturity in August 2027.
  • Continue to improve operational efficiencies, product quality, and throughput.
  • Pursue cost-saving initiatives and opportunities that enhance profitability.
  • Reduce extrusion, shirring, and printing waste through equipment upgrades.
  • Seek entry into new value-added lines of business.
  • Continue to review global businesses and may take additional restructuring actions where a path to sustained profitability is not feasible.

Key Dates

DateDescription
1970-01-01Viskase Holdings, Inc. (formerly Enzon Pharmaceuticals, Inc.) was incorporated in Delaware.
2025-06-20Agreement and Plan of Merger entered into between Enzon Pharmaceuticals, Inc., EPSC Acquisition Corp., and Viskase Companies, Inc.
2025-10-24First Amendment to the Agreement and Plan of Merger.
2025-12-31Covenant Relief Period for Senior Credit Facility ends.
2026-01-23Sixth Amendment to the credit agreement finalized, including a waiver on covenants for the year ended December 31, 2025.
2026-01-30Series C Exchange Offer commenced.
2026-03-10Ninth Amendment to the Section 382 Rights Agreement.
2026-03-11Majority of Enzon Common Stock holders approved the 1-for-100 reverse stock split.
2026-03-18Tenth Amendment to the Section 382 Rights Agreement.
2026-03-20Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Enzon Pharmaceuticals, Inc.
2026-03-23Eleventh Amendment to the Section 382 Rights Agreement.
2026-03-24Enzon effectuated the 1-for-100 reverse stock split.
2026-03-25IEH Parties exchanged Series C Preferred Stock for Enzon Common Stock.
2026-03-26Merger consummated; Viskase Companies became a wholly owned subsidiary of Viskase Holdings, Inc.
2026-03-26Certificate of Amendment, dated as of March 26, 2026.
2026-03-26Certificate of Elimination of Series A-1 Junior Participating Preferred Stock.
2026-03-31Quarterly period ended.
2026-04-16Seventh Amendment to the Credit Agreement finalized, extending the Maturity Date to August 13, 2027.
2026-05-01Amendment No. 1 to the Company's Current Report on Form 8-K filed with the SEC (containing audited financial statements for the year ended December 31, 2025).
2026-05-04Report signed by Thomas D. Davis and Michael Blecic.
2027-08-13Maturity Date of the Senior Credit Facility.

Recommendation

hold

While the company has extended its debt maturity and is integrating a significant merger, the persistent net losses, declining sales, and explicit statement of substantial doubt regarding its going concern status warrant caution. The company's ability to successfully refinance its debt is paramount. Until there is clearer evidence of a sustainable path to profitability and resolution of its liquidity concerns, a 'hold' recommendation is prudent for seasoned investors.

Keywords

Viskase Holdings, 10-Q Filing, Quarterly Report, Financial Results, Net Sales, Net Loss, Merger, Restructuring, Going Concern, Senior Credit Facility, Casings, Food Industry

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.